Key result
Propofol decreased peak shortening by 47 ± 6% in diabetic rat cardiomyocytes via a protein kinase C- and nitric oxide synthase-dependent pathway.
Propofol decreases cardiomyocyte contractility and myofilament Ca2+ sensitivity in diabetic rat hearts via a PKC- and NOS-dependent pathway.
Answers are grounded in this paper and cite their sources.
May warrant caution with propofol in diabetic patients; leaves open translation of PKC/NOS mechanisms to human myocardium.
BACKGROUND: The authors' objective was to assess the role of protein kinase C (PKC) and nitric oxide synthase (NOS) in mediating the effects of propofol on diabetic cardiomyocyte contractility, intracellular free Ca2+ concentration ([Ca2+]i), and myofilament Ca2+ sensitivity. METHODS: Freshly isolated ventricular myocytes were obtained from normal and diabetic rat hearts. [Ca2+]i and cell shortening were simultaneously measured in electrically stimulated, ventricular myocytes using fura-2 and video-edge detection, respectively. Actomyosin adenosine triphosphatase activity and troponin I (TnI) phosphorylation were assessed in [32P]orthophosphate-labeled myofibrils. Western blot analysis was used to assess expression of PKC and NOS. RESULTS: Propofol (10 microM) decreased peak shortening by 47 +/- 6% with little effect on peak [Ca2+]i (92 +/- 5% of control) in diabetic myocytes. Maximal actomyosin adenosine triphosphatase activity was reduced by 43 +/- 7% and TnI phosphorylation was greater (32 +/- 6%) in diabetic myofibrils compared with normal. Propofol reduced actomyosin adenosine triphosphatase activity by 17 +/- 7% and increased TnI phosphorylation in diabetic myofibrils. PKC inhibition prevented the propofol-induced increase in TnI phosphorylation and decrease in shortening. Expression of PKC-alpha, PKC-delta, PKC-epsilon, and constitutive NOS were up-regulated and inducible NOS was expressed in diabetic cardiomyocytes. NOS inhibition attenuated the propofol-induced decrease in shortening. CONCLUSION: Myofilament Ca2+ sensitivity and, to a lesser extent, peak [Ca2+]i are decreased in diabetic cardiomyocytes. Increases in PKC and NOS expression in combination with TnI phosphorylation seem to contribute to the decrease in [Ca2+]i and myofilament Ca2+ sensitivity. Propofol decreases [Ca2+]i and shortening via a PKC-, NOS-dependent pathway.
No takes yet. Share an insight, caveat, or question.
Wickley et al. (2006) studied Diabetic cardiomyopathy. Propofol vs. Control was evaluated on Peak shortening. Propofol decreased peak shortening by 47 ± 6% in diabetic rat cardiomyocytes via a protein kinase C- and nitric oxide synthase-dependent pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: